PFE Stock Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 4/6 |
Dividends | 5/6 |
Pfizer Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$33.62 |
52 Week High | US$54.93 |
52 Week Low | US$33.44 |
Beta | 0.55 |
1 Month Change | -9.16% |
3 Month Change | -13.19% |
1 Year Change | -23.45% |
3 Year Change | -6.61% |
5 Year Change | -23.03% |
Change since IPO | 1,036.45% |
Recent News & Updates
Recent updates
Pfizer: The Floor To This Decline Remains To Be Seen
Sep 02Pfizer: Searching For A Bottom
Aug 24Pfizer Stock: The Right Time To Buy Now (Technical Analysis)
Aug 17Pfizer's Unexpected Strength: Bullish Case Emerges Amid New Covid-19 Wave
Aug 11Pfizer: Significant Plunge, Offering Exceptional Buying Opportunity
Jul 24Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.41
Jul 17Pfizer: A 4.5% Dividend Yield Is A Gift
Jul 17Pfizer: A Worthwhile Dividend Play At A Cheap Valuation
Jul 10Pfizer: Come For The Dividend - Stay For The Dividend
Jun 28Pfizer's (NYSE:PFE) Dividend Will Be $0.41
Jun 26Shareholder Returns
PFE | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -1.3% | -2.1% | -1.5% |
1Y | -23.5% | 15.1% | 13.8% |
Return vs Industry: PFE underperformed the US Pharmaceuticals industry which returned 15.1% over the past year.
Return vs Market: PFE underperformed the US Market which returned 13.8% over the past year.
Price Volatility
PFE volatility | |
---|---|
PFE Average Weekly Movement | 2.6% |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 5.6% |
10% most volatile stocks in US Market | 14.3% |
10% least volatile stocks in US Market | 2.5% |
Stable Share Price: PFE is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: PFE's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1849 | 83,000 | Albert Bourla | https://www.pfizer.com |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands.
Pfizer Inc. Fundamentals Summary
PFE fundamental statistics | |
---|---|
Market Cap | US$189.82b |
Earnings (TTM) | US$21.49b |
Revenue (TTM) | US$77.94b |
8.8x
P/E Ratio2.4x
P/S RatioIs PFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PFE income statement (TTM) | |
---|---|
Revenue | US$77.94b |
Cost of Revenue | US$23.52b |
Gross Profit | US$54.42b |
Other Expenses | US$32.93b |
Earnings | US$21.49b |
Last Reported Earnings
Jul 02, 2023
Next Earnings Date
Oct 31, 2023
Earnings per share (EPS) | 3.81 |
Gross Margin | 69.82% |
Net Profit Margin | 27.58% |
Debt/Equity Ratio | 66.1% |
How did PFE perform over the long term?
See historical performance and comparison